The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia

• Autorzy: Styczynski J. , Wysocki M. , Debski R. , Kurylak A. , Balwierz W. , Rokicka-Milewska R. , Matysiak M. , Balcerska A. , Kowalczyk J. , Wachowiak J. , Sonta-Jakimczyk D. , Chybicka A.
• Języki publikacji: EN

Abstrakty

EN

Uptake and efflux of two anthracyclines, idarubicin (IDA) and daunorubicin (DNR), was studied in childhood acute leukemia samples. A comparison of IDA and DNR transport phenomena in relation to drug cytotoxicity and expression of P-glycoprotein (PGP) was made. Intracellular content of IDA/DNR was determined by flow cytometry using the fluorescent properties of the drugs. In vitro drug cytotoxicity was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. PGP expression was analysed by flow cytometry. The uptake and efflux rates were non-significantly higher for IDA than DNR. There were no differences between three types of leukemia with respect to drug content during accumulation and retention. After correction for the cell volume, intracellular concentration of both drugs in each moment of uptake and efflux was significantly lower in relapsed ALL and AML samples in comparison with initial ALL cells. Efflux, but not uptake, of both drugs was inversely correlated with PGP expression and IDA, but not DNR, cytotoxicity. The cytotoxicity was correlated with drug accumulation for both drugs and with drug retention for IDA. In conclusion, it seems that (1) intracellular content was related to the lipophilic properties of the drugs rather than to the type of leukemia, (2) decreased intracellular concentration of both drugs might have an impact on compromised therapy results in AML and relapsed ALL children, (3) IDA presents higher cytotoxicity, which possibly might be decreased by the presence of PGP. These results might have a practical impact on the rational design of new chemotherapy protocols.

Słowa kluczowe

EN

acute myeloblastic leukemia; drug resistance; P-glycoprotein; leukemia; acute leukemia; drug; idarubicin level; childhood; cytotoxicity; daunorubicin level; acute lymphoblastic leukemia; anthracycline

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2002
• Tom: 49
• Numer: 1
• Opis fizyczny: p.99-107,fig.

Twórcy

autor

Styczynski J.

• Medical University, Bydgoszcz, Poland

autor

Wysocki M.

autor

Debski R.

autor

Kurylak A.

autor

Balwierz W.

autor

Rokicka-Milewska R.

autor

Matysiak M.

autor

Balcerska A.

autor

Kowalczyk J.

autor

Wachowiak J.

autor

Sonta-Jakimczyk D.

autor

Chybicka A.

Bibliografia

• 1.Styczynski, J. & Wysocki, M. (2000) Mechanisms of drug resistance in leukemias: Therapeutic problem. Adv. Clin. Exp. Med. 9, 153-161.
• 2.Hortobagyi, G.N. (1997) Anthracyclines in the treatment of cancer. Drugs. 54 (Suppl. 4), 1-7.
• 3.McKenna, S.L. & Padua, R.A. (1997) Multidrug resistance in leukemia. Br. J. Haematol. 96, 659-674.
• 4.Skovsgaard, T. & Nissen, N.I. (1982) Membrane transport of anthracyclines. Pharmacol. Ther. 18, 293-311.
• 5.Siegfried, J.M., Burke, T.G. & Tritton, T.R. (1985) Cellular transport of anthracyclines by passive diffusion. Biochem. Pharmacol. 34, 593-598.
• 6.Den Boer, M.L., Pieters, R., Kazemier, K.M., Janka-Schaub, G.E., Henze, G. & Veerman, A.J.P. (1999) Relationship between the intacellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia. 13, 2023-2030.
• 7.Styczynski, J., Pieters, R., Huismans, D.R., Schuurhuis, G.J., Wysocki, M. & Veerman, A.J.P. (2000) In vitro drug resistance profiles in adult versus childhood acute lymphoblastic leukaemia. Br. J. Haematol. 110, 813-818.
• 8.Kaspers, G.J.L., Veerman, A.J.P., Pieters, R., Van Zantwijk, C.H., Klumper, E., Hahlen, K., De Waal, F.C. & Van Wering, E.R. (1994) In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia. 8, 24-29.
• 9.Weiss, RB. (1992) The antracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 19, 670-686.
• 10.Smeets, M.E.P., Raymakers, R.A.P., Vierwinden, G., Pennings, A.H.M., Boezman, J., Minderman, H. & De Witte, T.M. (1999) Idarubicin DNA intercalation is reduced by MRP1 and not PGP. Leukemia. 13, 1390-1398.
• 11.Pieters, R., Huismans, D.R., Loonen, A.H., Hahlen, K., Van Der Does-Van Den Berg, A., Van Wering, E.R. & Veerman, A.J.P. (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 338, 399-403.
• 12.Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1996) Biology of the multidrug resistance mediated by the multidrug resistance-associated protein, MRP. Eur. J. Cancer. 32A, 945-957.
• 13.Van den Heuvel-Eibrink, M.M., Sonneveld, P. & Pieters, R. (2000) The prognostic significance of membrane transport- associated multidrug resistance (MDR) proteins in leukemia. Int. J. Clin. Pharmacol. Ther. 38, 94-110.
• 14. Berman, E. & McBride, M. (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 79, 3267-3273.